Three Novel NF1 Gene Mutations in a Cohort of Bulgarian Neurofibromatoses Patients


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription Access

Abstract

Neurofibromatosis (NF) is a clinically heterogeneous autosomal dominant disorder. Three distinct forms have been identified: neurofibromatosis type 1 (NF1), type 2 (NF2) and schwannomatosis. In the present study, we report clinical and genetic findings in the NF1 and NF2 genes in a cohort of 27 Bulgarian patients, with 18 cases (67%) genetically verified. Both NF1 and NF2 genes were screened by Sanger sequencing on DNA samples. The Sanger negative samples were screened by Multiplex Ligation-dependent Probe Amplification (MLPA) for deletions and duplications. The results from genetic testing revealed three novel mutations and fifteen previously reported ones (13 in the NF1 gene and 2 in the NF2 gene). The novel variants in the NF1 gene are a splice site mutation c.4725-1G>A, a small deletion of five bases c.823delATCTT, p.Leu275ValfsTer14, and a single base duplication c.6547dupC, p.Arg2183ProfsTer11. The novel splice site mutation is manifested by multiple “café au lait” macules and neurofibromas. Both novel out of frame mutations were found in patients with multiple “café au lait” spots and focal epilepsy. A segmental neurofibromatosis (SNF1) is restricted to one or more body segments. Here we present a case with SNF1 caused by a somatic deletion of exons 1 to 12 of the NF1 gene which is manifested by multiple neurofibromas in the right hand. Two nonsense mutations are found in the NF2 gene. Our study adds three novel mutations to the NF1 mutation spectra and contributes to the clinical-genetic NF1-characterization. Here we report strikingly different phenotypic spectra caused by the same mutation in a single family. Our findings contribute to the genotype- phenotype correlations which are difficult to establish, due to the extremely complex NF phenotype being a combination of clinical features.

Keywords

About the authors

M. Glushkova

Department of Medical Chemistry and Biochemistry; Genetic Medico-Diagnostic Laboratory Genica

Author for correspondence.
Email: glushkova.mariq@gmail.com
Bulgaria, Sofia, 1431; Sofia, 1612

I. Yordanova

Genetic Medico-Diagnostic Laboratory Genica

Email: glushkova.mariq@gmail.com
Bulgaria, Sofia, 1612

T. Todorov

Genetic Medico-Diagnostic Laboratory Genica

Email: glushkova.mariq@gmail.com
Bulgaria, Sofia, 1612

V. Bojinova

Clinic of Child Neurology

Email: glushkova.mariq@gmail.com
Bulgaria, Sofia, 1113

M. Koleva

Clinic of Child Neurology

Email: glushkova.mariq@gmail.com
Bulgaria, Sofia, 1113

P. Dimova

Epilepsy Center, Department of Neurosurgery

Email: glushkova.mariq@gmail.com
Bulgaria, Sofia, 1431

I. Tournev

Department of Neurology; Department of Cognitive Science and Psychology

Email: glushkova.mariq@gmail.com
Bulgaria, Sofia, 1431; Sofia, 1618

L. Angelova

Department of Pediatric Diseases and Medical Genetics

Email: glushkova.mariq@gmail.com
Bulgaria, Varna, 9002

A. Todorova

Department of Medical Chemistry and Biochemistry; Genetic Medico-Diagnostic Laboratory Genica

Email: glushkova.mariq@gmail.com
Bulgaria, Sofia, 1431; Sofia, 1612

V. Mitev

Department of Medical Chemistry and Biochemistry

Email: glushkova.mariq@gmail.com
Bulgaria, Sofia, 1431

Supplementary files

Supplementary Files
Action
1. JATS XML

Copyright (c) 2018 Pleiades Publishing, Inc.